SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Medicamen Biotech - Quaterly Results

14 Feb 2026 Evaluate
The revenue zoomed 5.71% to Rs. 434.91 millions for the quarter ended December 2025 as compared to Rs. 411.42 millions during the corresponding quarter last year.Profit after tax improved marginally to Rs. 25.95  millions for the quarter ended December 2025 from Rs. 25.23 millions of corresponding previous quarter.Operating profit for the quarter ended December 2025 decreased to 56.14 millions as compared to 63.83 millions of corresponding quarter ended December 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 434.91 411.42 5.71 1241.65 1254.68 -1.04 1514.63 1723.86 -12.14
Other Income 5.35 1.41 279.43 13.78 10.06 36.98 62.25 23.03 170.30
PBIDT 56.14 63.83 -12.05 155.38 186.57 -16.72 227.83 282.74 -19.42
Interest 7.82 7.32 6.83 21.85 24.22 -9.79 30.45 43.77 -30.43
PBDT 48.32 56.51 -14.49 133.53 162.35 -17.75 197.38 238.97 -17.40
Depreciation 17.50 21.73 -19.47 53.33 64.87 -17.79 69.53 70.08 -0.78
PBT 30.82 34.78 -11.39 80.20 97.48 -17.73 127.85 168.89 -24.30
TAX 4.87 9.55 -49.01 15.82 26.98 -41.36 33.24 35.90 -7.41
Deferred Tax -1.57 -0.71 121.13 -3.14 -2.16 45.37 -3.15 -6.27 -49.76
PAT 25.95 25.23 2.85 64.38 70.50 -8.68 94.61 132.99 -28.86
Equity 135.63 127.15 6.67 135.63 127.15 6.67 127.15 127.15 0.00
PBIDTM(%) 12.91 15.51 -16.80 12.51 14.87 -15.84 15.04 16.40 -8.29

Medicamen Biotech Share Price

242.45 3.95 (1.66%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×